-+ 0.00%
-+ 0.00%
-+ 0.00%

DOGWOOD ENROLLS FIRST 200 PATIENTS IN ONGOING HALNEURON® PHASE 2B CHEMOTHERAPY INDUCED NEUROPATHY TRIAL; TOP-LINE DATA EXPECTED IN FALL 2026

Reuters·07/20/2026 12:30:00

Please log in to view news